These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 27824816)

  • 41. 2010 FDA drug approvals.
    Mullard A
    Nat Rev Drug Discov; 2011 Feb; 10(2):82-5. PubMed ID: 21283092
    [No Abstract]   [Full Text] [Related]  

  • 42. NerveCenter: FDA requirements for generic drug applications.
    Ann Neurol; 2010 Sep; 68(3):A11. PubMed ID: 20818779
    [No Abstract]   [Full Text] [Related]  

  • 43. Accelerating evidence gathering and approval of precision medicine therapies: the FDA takes aim at rare mutations.
    Issa AM; Thorogood A; Joly Y; Knoppers BM
    Genet Med; 2019 Mar; 21(3):542-544. PubMed ID: 29988078
    [No Abstract]   [Full Text] [Related]  

  • 44. FDA standards--good enough for government work?
    Avorn J
    N Engl J Med; 2005 Sep; 353(10):969-72. PubMed ID: 16148281
    [No Abstract]   [Full Text] [Related]  

  • 45. Regulatory watch: Evaluating the potential for digital submission of expedited premarket safety reports to the FDA.
    Khozin S; Chuk M; Kim T; Kim G; Pazdur R; De S; Sahoo S
    Nat Rev Drug Discov; 2016 Sep; 15(10):670-1. PubMed ID: 27681787
    [No Abstract]   [Full Text] [Related]  

  • 46. FDA performance goals for approving drugs and biologics.
    Miller JD
    JAMA; 2009 Jul; 302(2):189-91. PubMed ID: 19584348
    [No Abstract]   [Full Text] [Related]  

  • 47. Skipping toward personalized molecular medicine.
    Hoffman EP
    N Engl J Med; 2007 Dec; 357(26):2719-22. PubMed ID: 18160693
    [No Abstract]   [Full Text] [Related]  

  • 48. EMA reconsiders 'read-through' drug against Duchenne muscular dystrophy following appeal.
    Mullard A
    Nat Biotechnol; 2014 Aug; 32(8):706. PubMed ID: 25101726
    [No Abstract]   [Full Text] [Related]  

  • 49. Towards regulatory endorsement of drug development tools to promote the application of model-informed drug development in Duchenne muscular dystrophy.
    Conrado DJ; Larkindale J; Berg A; Hill M; Burton J; Abrams KR; Abresch RT; Bronson A; Chapman D; Crowther M; Duong T; Gordish-Dressman H; Harnisch L; Henricson E; Kim S; McDonald CM; Schmidt S; Vong C; Wang X; Wong BL; Yong F; Romero K;
    J Pharmacokinet Pharmacodyn; 2019 Oct; 46(5):441-455. PubMed ID: 31127458
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Priority drugs well represented among 1998 approvals. FDA says all performance goals were met.
    Miller JL
    Am J Health Syst Pharm; 1999 Mar; 56(5):408, 411-2. PubMed ID: 10096697
    [No Abstract]   [Full Text] [Related]  

  • 51. Perspectives on the Current State of the Biosimilar Regulatory Pathway in the United States.
    Dougherty MK; Zineh I; Christl L
    Clin Pharmacol Ther; 2018 Jan; 103(1):36-38. PubMed ID: 29152721
    [TBL] [Abstract][Full Text] [Related]  

  • 52. United States Food and Drug Administration requirements for approval of generic drug products.
    Meyer MC
    J Clin Psychiatry; 2001; 62 Suppl 5():4-9; discussion 23-4. PubMed ID: 11305846
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Relocating abroad. FDA sends staff overseas to help monitor imports.
    Lee J
    Mod Healthc; 2011 Oct; 41(43):32. PubMed ID: 22111150
    [No Abstract]   [Full Text] [Related]  

  • 54. Corticosteroids in Duchenne muscular dystrophy: a reappraisal.
    Wong BL; Christopher C
    J Child Neurol; 2002 Mar; 17(3):183-90. PubMed ID: 12026233
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evidence-based medicine and drug-eluting stents.
    O'Dwyer J
    Med Device Technol; 2004 May; 15(4):34-7. PubMed ID: 15303564
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Perspectives on the U.S. FDA Bioresearch Monitoring Program.
    Gamet JE
    Qual Assur; 1995 Mar; 4(1):12-9. PubMed ID: 8520859
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Rivaroxaban: can we trust the evidence?
    Cohen D
    BMJ; 2016 Feb; 352():i575. PubMed ID: 26843102
    [No Abstract]   [Full Text] [Related]  

  • 58. When EMA and FDA decisions conflict: differences in patients or in regulation?
    Wolfe SM
    BMJ; 2013 Aug; 347():f5140. PubMed ID: 23970394
    [No Abstract]   [Full Text] [Related]  

  • 59. Ending the 50-year drought of FDA drug approval for SLE.
    Merrill JT
    Bull NYU Hosp Jt Dis; 2011; 69(3):238-42. PubMed ID: 22035436
    [No Abstract]   [Full Text] [Related]  

  • 60. European Medicines Agency review of ataluren for the treatment of ambulant patients aged 5 years and older with Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene.
    Haas M; Vlcek V; Balabanov P; Salmonson T; Bakchine S; Markey G; Weise M; Schlosser-Weber G; Brohmann H; Yerro CP; Mendizabal MR; Stoyanova-Beninska V; Hillege HL
    Neuromuscul Disord; 2015 Jan; 25(1):5-13. PubMed ID: 25497400
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.